Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 4;13(1):73.
doi: 10.1186/s13023-018-0815-5.

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

Emel Aygören-Pürsün  1 , Markus Magerl  2 , Andreas Maetzel  3   4 , Marcus Maurer  2
Affiliations

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

Emel Aygören-Pürsün et al. Orphanet J Rare Dis. .

Abstract

Background: Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management.

Methods: We systematically searched the medical literature to identify abstracts of interest indexed between 1948 and March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany and France. For hereditary angioedema (C1-INH-HAE) and C1-inhibitor related acquired angioedema (C1-INH-AAE), publications had to contain original epidemiologic data collection within a defined geographical area. Hereditary angioedema with normal C1-INH was not included in the analysis due to lack of clearly defined criteria.

Results: We identified 4 relevant publications on the prevalence of ACEI-AE, 6 on the prevalence of C1-INH-HAE, and 1 on the prevalence of C1-INH-AAE. The 1st year cumulative incidence of ACEI-AE was estimated to vary between 0.12 (population-based analyses) and 0.30 (meta-analyses of clinical trials) per 100 patient-years. The population prevalence of ACEI-AE was modeled to vary between 7 and 26 in 100,000. The prevalence of C1-INH-HAE was estimated to vary between 1.1 and 1.6 per 100,000. The prevalence of C1-INH-AAE was estimated to be 0.15 per 100,000 in one epidemiological investigation of AAE in Denmark.

Conclusions: Epidemiological evidence on Bk-AE is limited to North America and Europe. ACEI-AE is more common than C1-INH-HAE (~ 10:1), which is more common than C1-INH-AAE (~ 10:1). More studies are needed to comprehensively assess the epidemiological burden of Bk-AE.

Keywords: ACE-inhibitor; Angioedema; Bradykinin; C1-inhibitor; Epidemiology.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable. This research is exempt from IRB review (Ethics-Committee of the Johann Wolfgang Goethe University).

Competing interests

EAP: Consultant and/ or Speaker and/or research grant from: Biocryst, CSL Behring, Shire, Pharming.

MMag: Consultant and/ or Speaker and/or research grant from: Biocryst, CSL Behring, Shire, Pharming.

AMae: Currently an employee of Kalvista Pharmaceuticals, Inc. and in the past was employee of BioCryst Pharmaceuticals.

MMau: Consultant and/ or Speaker and/or research grant from: Alnylam, Biocryst, CSL Behring, Shire, Pharming, Pharvaris.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Madsen F, Attermann J, Linneberg A. Epidemiology of non-hereditary angioedema. Acta Derm Venereol. 2012;92:449–581. doi: 10.2340/00015555-1389. - DOI - PubMed
    1. Magerl M, Bader M, Gompel A, Joseph K, Kaplan AP, Kojda G, et al. Bradykinin in health and disease: proceedings of the Bradykinin symposium 2012, Berlin 23-24 August 2012. Inflamm Res. 2014;63:173–178. doi: 10.1007/s00011-013-0693-1. - DOI - PubMed
    1. Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, et al. New topics in bradykinin research. Allergy. 2011;66:1397–1406. doi: 10.1111/j.1398-9995.2011.02686.x. - DOI - PubMed
    1. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–1697. doi: 10.1016/S0140-6736(97)09137-X. - DOI - PubMed
    1. Rocha ESM, Beraldo WT, Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol. 1949;156:261–273. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources